In vitro application of phosphate alone increased the expression of LVH-related markers (15) and treatment with phosphate binder improved hyperphosphatemia and LVH, although serum FGF23 levels remained higher in CKD mice (38). Here, FGF23 is linked to chronic kidney disease.